Asparaginase : an old drug with new questions

• Autor(a) principal: Cecconello, Daiane Keller
• Data de Publicação: 2020
• Outros Autores: Magalhães, Mariana Rodrigues, Werlang, Isabel Cristina Ribas, Lee, Maria Lucia de Martino, Michalowski, Mariana Bohns, Daudt, Liane Esteves
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/234486
• topic: Asparaginase; Hipersensibilidade; Inativação metabólica; Leucemia-linfoma linfoblástico de células precursoras; Hypersensitivity; Silent inactivation; Acute lymphoblastic leukemia

The long-term outcome of acute lymphoblastic leukemia has improved dramatically due to the development of more effective treatment strategies. L-asparaginase (ASNase) is one of the main drugs used and causes death of leukemic cells by systematically depleting the nonessential amino acid asparagine. Three main types of ASNase have been used so far: native ASNase derived from Escherichia coli, an enzyme isolated from Erwinia chrysanthemi and a pegylated form of the native E. coli ASNase, the ASNase PEG. Hypersensitivity reactions are the main complication related to this drug. Although clinical allergies may be important, a major concern is that antibodies produced in response to ASNase may cause rapid inactivation of ASNase, leading to a worse prognosis. This reaction is commonly referred to as silent hypersensitivityor silent inactivation. We are able to analyze hypersensitivity and inactivation processes by the measurement of the ASNase activity. The ability to individualize the ASNase therapy in patients, adjusting the dose or switching patients with silent inactivation to an alternate ASNase preparation may help improve outcomes in those patients. This review article aims to describe the pathophysiology of the inactivation process, how to diagnose it and finally how to manage it.